In this study, researchers are looking at two ways of giving a medicine called pembrolizumab to people with different types of tumors. One way is through an injection under the skin, called subcutaneous (SC), and the other is through a needle into a vein, called intravenous (IV). Pembrolizumab is used to treat cancer. The study's goal is to see which method people like better. They are not testing to see if one way works better than the other.

Eligibility: You can join if you have certain types of cancer, like skin, lung, or kidney cancer, and meet some other health conditions. If you have other serious health issues, you might not be able to join.

• The study involves trying both SC and IV methods.
• You'll need to have a certain health status to participate.
• There are some health conditions that may exclude you from the study.

Participants need to have a life expectancy of at least 3 months and might receive compensation for taking part in the study. The study does not involve testing any new drugs, just the method of giving them.